Session

Gallium-PSMA and other tracers for prostate cancer: Do they really help?

Poster Session 45

  • Location:
    Room 14c (ICM, Level 1)
  • Chairs:
     F. Abdollah, West Bloomfield (US)
     G. Ploussard, Toulouse (FR)
     T. Wiegel, Ulm (DE)
  • Aims and objectives of this session

    Gallium-PSMA PET is suggested to be an emerging tool in staging of prostate cancer. Conflicting data, however, have been published concerning its use for lymph node staging or diagnosis of prostate cancer relapse. This session will highlight the most recent data on new PET tracers for prostate cancer.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
Is seeing more enough to do more?
 T. Wiegel, Ulm (DE)
557
Localization of primary prostate cancer by simultaneous 68Gallium-HBED-CC-PSMA PET and multiparametric MRI

By: Eiber M.1, Weirich G.2, Nguyen N.3, Holzapfel K.4, Souvatzolgou M.1, Haller B.5, Rauscher I.1, Beer A.6, Wester H.-J.7, Westenfelder K.3, Gschwend J.3, Schwaiger M.1, Maurer T.3

Institutes: 1Technical University of Munich, Dept. of Nuclear Medicine, Munich, Germany, 2Technical University of Munich, Dept. of Pathology, Munich, Germany, 3Technical University of Munich, Dept. of Urology, Munich, Germany, 4Technical University of Munich, Dept. of Radiology, Munich, Germany, 5Technical University of Munich, Dept. of Medical Statistics and Epidemiology, Munich, Germany, 6University of Ulm, Dept. of Nuclear Medicine, Ulm, Germany, 7Technical University of Munich, Dept. of Pharmaceutical Radiopharmacy, Munich, Germany

* 558
Diagnostic efficacy of 68Ga-PSMA PET for lymph node staging and metastatic distribution in patients with intermediate to high-risk prostate cancer

By: Maurer T.1, Gschwend J.1, Pähr L.1, Rauscher I.2, Souvatzoglou M.2, Haller B.3, Weirich G.4, Wester H-J.5, Heck M.1, Hacker C.1, Kübler H.1, Beer A.6, Schwaiger M.2, Eiber M.2

Institutes: 1Technical University of Munich, Dept. of Urology, Munich, Germany, 2Technical University of Munich, Dept. of Nuclear Medicine, Munich, Germany, 3Technical University of Munich, Institute for Medical Statistics and Epidemiology, Munich, Germany, 4Technical University of Munich, Institute of Pathology, Munich, Germany, 5Technical University of Munich, Dept. of Pharmaceutical Radiochemistry, Munich, Germany, 6University of Ulm, Dept. of Nuclear Medicine, Ulm, Germany

559
Prospective evaluation of 68Ga-PSMA positron emission tomography/computerized tomography for preoperative lymph node staging in prostate cancer

By: Van Leeuwen P.1, Emmett L.2, Ho B.2, Delprado W.3, Stricker P.1

Institutes: 1St. Vincent’s Prostate Cancer Centre, Dept. of Urology, Sydney, Australia, 2St. Vincent’s Public Hospital, Dept. of Diagnostic Imaging, Sydney, Australia, 3University of Notre Dame, Dept. of Histopathology, Sydney, Australia

560
68Ga-PSMA PET/CT provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer

By: Herlemann A.1, Wenter V.2, Kretschmer A.1, Bartenstein P.2, Stief C.1, Gratzke C.1, Fendler W.2

Institutes: 1Ludwig-Maximilians-University Munich, Dept. of Urology, Munich, Germany, 2Ludwig-Maximilians-University Munich, Dept. of Nuclear Medicine, Munich, Germany

561
Evaluation of detection rate of 68Ga-PSMA PET/CT for biochemical recurrence after radical prostatectomy

By: Paffen M.L.J.E.1, Murphy D.2, Costello A2, Hicks R.3, Hoffman M.3

Institutes: 1Royal Melbourne Hospital, Dept. of Urology, Wodonga, Australia, 2Royal Melbourne Hospital, Dept. of Urology, Melbourne, Australia, 3Peter MacCallum Cancer Centre, Dept. of Nuclear Medicine, Melbourne, Australia

562
Accuracy of 18f-facbc (anti1-amino-3-18f-fluorocyclobutane-1-carboxylic acid) in prostate cancer relapse: Results of a prospective trial

By: Pultrone C.V.1, Bianchi L.1, Brunocilla E.1, Fanti S.2, Nanni C.2, Zanoni L.2, Matti A.2, Borghesi M.3, Bravi C.1, Martorana G.1, Schiavina R.1

Institutes: 1St Orsola Hospital, University of Bologna, Dept. of Urology, Bologna, Italy, 2St Orsola Hospital, University of Bologna, Dept. of Nuclear Medicine, Bologna, Italy, 3St Orsola Hospital, University of Bologna, Dept. of Urology and Medical and Surgical Sciences, Bologna, Italy

563
The diagnostic accuracy of 68Ga-PSMA-PET/CT for detection of lymph node metastases in the setting of salvage lymph node dissection

By: Jilg C.A.1, Drendel V.2, Beck T.3, Rischke C.3, Grosu A.4, Werner M.2, Wetterauer U.1, Meyer P.3, Schultze-Seemann W.1

Institutes: 1University Medical Center Freiburg, Dept. of Urology, Freiburg, Germany, 2University Medical Center Freiburg, Dept. of Pathology, Freiburg, Germany, 3University Medical Center Freiburg, Dept. of Nuclear Medicine, Freiburg, Germany, 4University Medical Center Freiburg, Dept. of Radiation Oncology, Freiburg, Germany

564
The role of 68Ga-PSMA PET/CT in the diagnosis and therapeutic decision making of oligometastatic recurrence after radical prostatectomy

By: Tosco L.1, Gheysens O.2, Deroose C.2, De Meerleer G.3, Haustermans K.4, Everaerts W.1, Cromphout L.1, Van Poppel H.1, Van Laere K.2, Joniau S.1, Goffin K.2

Institutes: 1UZ Leuven, Dept. of Development and Regeneration, Leuven, Belgium, 2UZ Leuven, Dept. of Nuclear Medicine, Leuven, Belgium, 3University Hospitals Ghent, Dept. of Radiotherapy, Ghent, Belgium, 4UZ Leuven, Dept. of Radiotherapy, Leuven, Belgium

565
Probability of positive PET imaging with a [68Ga]-labelled PSMA ligand based on PSA value in patients with biochemical recurrent prostate cancer after radical prostatectomy

By: Cromphout L.1, Tosco L.1, Everaerts W.1, Albersen M.1, Gheysens O.2, Deroose C.2, Van Laere K.2, Goffin K.2, Joniau S.1

Institutes: 1UZ Leuven, Dept. of Urology, Leuven, Belgium, 2UZ Leuven, Dept. of Nuclear Medicine, Leuven, Belgium

566
68Gallium-HBED-CC-PSMA PET compared to conventional bone scintigraphy for evaluation of bone metastases in prostate cancer patients

By: Eiber M.1, Pyka T.1, Okamoto S.1, Rauscher I.1, Dahlbender M.2, Tauber R.2, Retz M.2, Gschwend J.2, Schwaiger M.1, Maurer T.2

Institutes: 1Technical University of Munich, Dept. of Nuclear Medicine, Munich, Germany, 2Technical University of Munich, Dept. of Urology, Munich, Germany

567
PET imaging of therapy-naïve primary prostate cancer patients using the GRPr-targeting ligand Sarabesin 3

By: Bakker I.L.1, Fröberg A.C.1, Busstra M.B.2, Van Leenders G.J.L.H.3, De Blois E.1, Schoots I.4, Veenland J.4, Maina T.5, Van Weerden W.M.2, Nock B.A.5, De Jong M.1

Institutes: 1Erasmus MC, Dept. of Nuclear Medicine, Rotterdam, The Netherlands, 2Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, 3Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, 4Erasmus MC, Dept. of Radiology, Rotterdam, The Netherlands, 5NCSR “Demokritos”, Dept. of Radiochemistry, Athens, Greece

568
PSMA pet improves diagnostic accuracy of mpMRI in localised prostate cancer as confirmed by whole mount histopathology: Implications for selection and assessment for active surveillance and focal therapy

By: Rhee H.1, Thomas P.2, Shepherd B.3, Greenslade S.4, Vela I.1, Russell P.5, Nelson C.5, Chung E.6, Wood G.7, Malone G.8, Wood S.8, Heathcote P.8

Institutes: 1Princess Alexandra Hospital/ Queensland University of Technology, Dept. of Urology and Australian Prostate Cancer Research Centre – Queensland, Woolloongabba, Australia, 2Royal Brisbane and Women’s Hospital, Dept. of Nuclear Medicine, Brisbane, Australia, 3Princess Alexandra Hospital, Dept. of Anatomical Pathology, Woolloongabba, Australia, 4Princess Alexandra Hospital, Dept. of Radiology, Woolloongabba, Australia, 5Queensland University of Technology, Australian Prostate Cancer Research Centre – Queensland, Woolloongabba, Australia, 6Princess Alexandra Hospital, Dept. of Urology, Woolloongabba, Australia, 7Greenslopes Private Hospital, Dept. of Urology, Brisbane, Australia, 8Princess Alexandra Hospital/Greenslopes Private Hospital, Dept. of Urology, Brisbane, Australia